Why the study?
Pulmonary tumor thrombotic microangiopathy is a severe complication of malignancy characterized by rapidly progressive pulmonary hypertension and a dismal prognosis.
Pulmonary artery blood cytology during right heart catheterization is a safe and effective method for the premortem diagnosis of pulmonary tumor thrombotic microangiopathy, and systemic chemotherapy can improve its hemodynamics.
PTTM warrants consideration in cancer patients with unexplained dyspnea; case report leaves optimal diagnosis and management unresolved.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a severe complication of malignancy, characterized by rapidly progressive pulmonary hypertension and a dismal prognosis. This report describes the case of a 71-year-old woman with a history of estrogen receptor (ER)-positive left breast cancer who developed PTTM. She presented with exertional dyspnea and a cough. Arterial blood gas analysis revealed hypoxemia with an elevated alveolar-arterial oxygen gradient. Chest computed tomography (CT) showed diffuse ground-glass and nodular opacities without obvious pulmonary embolism (PE). Echocardiography revealed right ventricular enlargement and moderate pulmonary hypertension. Right heart catheterization confirmed severe pulmonary hypertension with a mean pulmonary artery pressure of 46 mmHg and pulmonary vascular resistance of 844 dynes/sec/cm⁵. After transbronchial lung biopsy (TBLB) and bronchoalveolar lavage (BAL) failed to yield a diagnosis, PTTM was confirmed by detecting malignant cells via cytology of blood aspirated from the pulmonary artery during catheterization. The administration of systemic chemotherapy resulted in a marked improvement in hemodynamics, radiological findings, and symptoms, allowing her to be weaned from home oxygen therapy.
No takes yet. Share an insight, caveat, or question.
Tajima et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: